ORTX News and Press, Orchard Therapeutics plc From 09/26/21

The following slide deck was published by Orchard Therapeutics plc in conjunction with this event. For further details see: Orchard Therapeutics (ORTX) Investor Prentation - Slideshow

Novel Discovery Research in HSC-generated Antigen-specific Regulatory T Cells Disclosed HSC Gene Therapy Also Provides Advantages for Delivery of Monoclonal Antibodies New Applications Present Opportunities for Future Partnerships BOSTON and LONDON, Sept. 14, 2021 ...

Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie Meltzer, Ph.D., promoted to chief medical officer Appointments reinforce compan...

BOSTON and LONDON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D Investor Event on Tuesday, September 14, 2021, from 7:00 a.m. to 8:00 a.m. ET. Members of Orchard&#x...

BOSTON and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Compensation Committee of Orchard’s Board of Directors approved the grant of non-statutory stock options to four new employees to purchase...

BOSTON and LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be available for one-on-one meetings at the following investor conferences: Goldman Sachs 11 ...

ORTX is a developer of autologous gene therapies for rare diseases. Recent regulatory updates have taken the stock down. While there's a lot of promise in science, we will stay on the sidelines. For further details see: Orchard Therapeutics: Cutting-Edge Science Beset Wi...

Orchard Therapeutics (NASDAQ:ORTX): Q2 GAAP EPS of -$0.29 beats by $0.04. Cash, cash equivalents and investments as of June 30, 2021, were $269.3 million compared to $191.9 million as of December 31, 2020. Shares +0.36% PM. Press Release For further details see: Orchard Therapeutics EPS...

Regulatory feedback obtained on OTL-200 (MLD) and OTL-203 (MPS-IH) programs New HAE collaboration with Pharming Group highlights broad potential for HSC gene therapy Multiple presentations from neurometabolic programs at MPS Symposia including additional follow-up in MPS...

Orchard Therapeutics plc (NASDAQ:ORTX) traded today at a new 52-week low of $3.00. So far today approximately 149,000 shares have been exchanged, as compared to an average 30-day volume of 619,000 shares. Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integr...